Introduction to Rare Spinal Tumors

Effective spinal anaplastic ependymoma treatment remains a clinical challenge due to the rarity and aggressive nature of these tumors. A recent case report highlights a 65-year-old male who achieved 35-month survival despite having a high-grade, MYCN-amplified lesion. This specific molecular marker typically signifies a poor prognosis. Therefore, the successful management of this case provides valuable insights into viable therapeutic strategies for clinicians.

Clinical Observation and Diagnosis

The patient presented with a dorsal intradural extramedullary lesion at the T2-3 level. Additionally, MRI scans revealed leptomeningeal spread within the lumbar spine. Diagnostic evaluations eventually confirmed a WHO grade 3 ependymoma. Notably, the tumor exhibited MYCN amplification, which clinicians associate with rapid progression. Consequently, the medical team prioritized a multidisciplinary approach to balance tumor control with neurological preservation.

Advancements in Spinal Anaplastic Ependymoma Treatment

Surgeons performed a subtotal resection because the tumor adhered densely to the spinal cord. They left approximately 10% of the tumor in situ to avoid permanent neurological deficits. Following surgery, the patient received adjuvant proton beam therapy within two weeks. The protocol included craniospinal irradiation of 3600 cGy, followed by a localized boost reaching 5400 cGy. This targeted radiation helps minimize damage to surrounding healthy tissue while addressing systemic dissemination.

The patient recovered remarkably well and regained full strength and function. Furthermore, serial MRI studies at 22 months showed stable spinal disease without any intracranial spread. This outcome suggests that subtotal resection combined with aggressive radiation is effective. Specifically, proton beam therapy may offer a survival advantage in cases where gross-total resection is impossible.

Frequently Asked Questions

What is the significance of MYCN amplification in spinal tumors?

MYCN amplification is a molecular marker indicating an aggressive subtype of ependymoma. It usually predicts a higher risk of recurrence and leptomeningeal spread compared to non-amplified tumors.

When is subtotal resection preferred over total resection?

Surgeons prefer subtotal resection when the tumor is densely adherent to the spinal cord or nerves. This approach aims to preserve the patient’s motor and sensory functions when a complete removal poses too much risk.

How does proton beam therapy benefit these patients?

Proton beam therapy allows for precise radiation delivery with minimal exit dose. This protects vital organs and healthy spinal tissue, which is crucial during high-dose craniospinal irradiation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Ezzat B et al. A rare case of intradural extramedullary anaplastic ependymoma: a 35-month survival update following resection and adjuvant proton beam radiation therapy. Illustrative case. J Neurosurg Case Lessons. 2026 May 18. doi: undefined. PMID: 42150194.

2. Ghasemi DR et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol. 2019;138(6):1075-1089.

3. Medscape Reference. Ependymoma Guidelines. 2023.